Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Adjunctive D-Cycloserine to Enhance the Antidepressant Effects of Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder
FY 2023-24
Summary
Enhancing Non-Invasive Brain Stimulation Treatments for Depression
Major Depressive Disorder (MDD) is common and debilitating. Although medications and psychotherapy are effective for some, they do not work for all patients. Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive neurostimulation technique that represents a novel option that is proven to be safe and effective in the treatment of MDD. rTMS works by using magnetic field pulses to stimulate targeted networks in the brain that are implicated in MDD. It is believed neurostimulation can change the functioning of these brain networks by influencing the connection strength of neurons in an activity-dependent process called synaptic plasticity. However, as with other treatments, rTMS is not effective for all patients. We believe we can improve rTMS therapy by augmenting the pharmacological mechanisms of synaptic plasticity. The N-methyl-D-aspartate receptor (NMDAr) is a key regulator of synaptic plasticity, and our pilot data suggests we can successfully enhance the antidepressant effects of rTMS by facilitating this receptor using a medication called D-cycloserine. In this project, we will use a randomized placebo-controlled clinical trial to determine whether D-cycloserine in combination with the leading rTMS treatment protocol called intermittent theta-burst stimulation (iTBS) can enhance antidepressant effects. Participants with MDD will all receive iTBS treatment to the left dorsolateral prefrontal cortex, however they will be randomized to receive either D-cycloserine or a placebo capsule in conjunction with their treatments. If successful, this could represent a simple and low-cost means of enhancing the existing TMS infrastructure to reduce the burden of MDD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
505950
Name
Cole Jaeden
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Adjunctive D-Cycloserine to Enhance the Antidepressant Effects of Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Intermittent Theta Burst Stimulation; Major Depressive Disorder; Neuromodulation; Nmda Receptor; Repetitive Transcranial Magnetic Stimulation; Synaptic Plasticity
Abstract
Enhancing Non-Invasive Brain Stimulation Treatments for Depression
Major Depressive Disorder (MDD) is common and debilitating. Although medications and psychotherapy are effective for some, they do not work for all patients. Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive neurostimulation technique that represents a novel option that is proven to be safe and effective in the treatment of MDD. rTMS works by using magnetic field pulses to stimulate targeted networks in the brain that are implicated in MDD. It is believed neurostimulation can change the functioning of these brain networks by influencing the connection strength of neurons in an activity-dependent process called synaptic plasticity. However, as with other treatments, rTMS is not effective for all patients.<br />We believe we can improve rTMS therapy by augmenting the pharmacological mechanisms of synaptic plasticity. The N-methyl-D-aspartate receptor (NMDAr) is a key regulator of synaptic plasticity, and our pilot data suggests we can successfully enhance the antidepressant effects of rTMS by facilitating this receptor using a medication called D-cycloserine. In this project, we will use a randomized placebo-controlled clinical trial to determine whether D-cycloserine in combination with the leading rTMS treatment protocol called intermittent theta-burst stimulation (iTBS) can enhance antidepressant effects. Participants with MDD will all receive iTBS treatment to the left dorsolateral prefrontal cortex, however they will be randomized to receive either D-cycloserine or a placebo capsule in conjunction with their treatments. <br />If successful, this could represent a simple and low-cost means of enhancing the existing TMS infrastructure to reduce the burden of MDD.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cole, Jaeden
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~